TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $110.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments